USP 800 Chemotherapy Compounding Gloves: Evidence Checks for Buyers

Evidence-first buyer guide to USP 800 chemotherapy compounding gloves, covering public USP status, NIOSH list context, ASTM D6978 test proof, and evidence to request before hospital or pharmacy approval.

Author and evidence boundary for this compliance article

Publication byline: Vincent Xi, Editorial Author. Author profile: https://www.glovemark.com/authors/vincent-xi/. For Article or BlogPosting structured data, the author should be a Person named Vincent Xi, with jobTitle Editorial Author and the same profile URL. This article does not claim private glove testing, factory visits, customer projects, certifications, tenure, or personal hazardous-drug handling experience. The recommendations below are framed as buyer evidence checks drawn from supplied public source material.

Why USP 800 scope changes glove approval

Hospital and pharmacy buyers should treat USP 800 chemotherapy compounding gloves as part of a hazardous-drug handling system, not as a standalone product label. USP describes the chapter as practice and quality standards for handling hazardous drugs to promote patient safety, worker safety, and environmental protection. The scope covers handling activities such as receipt, storage, compounding, dispensing, administration, and disposal of sterile and nonsterile products and preparations. That scope matters because glove approval has to connect product evidence with the facility's occupational safety plan. A glove can be marketed for chemotherapy handling and still leave open questions about sterile compounding use, double gloving, replacement interval, breakthrough-time documentation, and whether the exact glove model was tested. USP's revision bulletin states that USP 800 became official on December 1, 2019, and USP's FAQ states that it became compendially applicable to the extent specified in related compounding chapters on November 1, 2023. Those dates are not product approvals; they are compliance context for the buyer's own program.

Separate public guidance from supplier claims

A useful approval file separates three evidence layers. The first layer is public hazardous-drug guidance: USP scope, USP status, and the current NIOSH list context. The second layer is product performance evidence: chemotherapy permeation testing, powder-free status, sterile outer glove suitability when needed, and use instructions. The third layer is local implementation: SOPs, risk assessment, training, inspection, donning and doffing, and disposal. The reason to keep these layers separate is simple: standards and guidance do different jobs. USP 800 tells healthcare entities how hazardous drugs should be handled in healthcare settings. NIOSH helps identify hazardous drugs and informs risk assessment. A supplier's glove literature may state that a glove is chemo-tested, but it should not be accepted as proof that the facility has satisfied all handling obligations. Buyers should ask the supplier for documents that match the exact glove being approved, then place those documents inside the facility's own USP 800 implementation record.

What to request for ASTM D6978 chemotherapy glove evidence

Medline's USP glove guidance states that gloves must be powder-free and chemo-tested to ASTM D6978. For procurement, that should trigger a document request rather than a yes-or-no checkbox. Ask for the complete chemotherapy-drug permeation report or a controlled technical summary that names ASTM D6978, the tested glove material, the exact product name, SKU or catalog family, tested drug panel, reported breakthrough or permeation result, laboratory identity, report date, and any conditions or exclusions stated by the test report. Do not assume that a box-panel claim covers every glove variation. A buyer should confirm whether the tested item matches the submitted product in material, formulation, colorant where relevant, thickness specification, cuff design, sterile or nonsterile format, and manufacturing version. If a supplier offers several glove families under similar branding, require evidence for the candidate glove, not only a related glove. If the report is a summary, ask whether the facility's pharmacy, infection prevention, and occupational safety reviewers can see the complete underlying report before formulary or catalog approval. Medline's brochure also says chemotherapy gloves must be changed every 30 minutes unless otherwise recommended by the chemo panel on glove boxes for breakthrough times. That statement is useful for a buyer checklist, but it does not replace local SOPs or the supplier's specific breakthrough-time evidence. If a supplier recommends a longer or shorter interval, require the supporting data and have the pharmacy team verify that it fits the handling task.

NIOSH and OSHA context for buyer files

USP's FAQ identifies the NIOSH List of Hazardous Drugs in Healthcare Settings, 2024, as the most current NIOSH list referenced in that FAQ. For glove buying, NIOSH context should be used to connect the facility's drug inventory to exposure risk. The list helps the buyer and pharmacy team ask which hazardous drugs are handled, whether antineoplastic drugs are involved, where the handling occurs, and which tasks create contact risk for the hands. NIOSH context does not certify a glove. It supports the risk assessment that decides when chemotherapy-tested gloves, double gloving, sterile outer gloves, and specific change intervals are needed. Buyers should therefore ask suppliers for glove performance evidence, while asking the facility's pharmacy and EHS teams to connect that evidence to the drug list and SOPs. No dedicated OSHA source URL was supplied for this article, so OSHA should be treated here as a verification gap rather than a quoted requirement. Hospital buyers should have EHS or counsel confirm current OSHA obligations for hazard communication, PPE selection, training, and employee protection using current OSHA materials. A supplier statement that a glove is suitable for chemotherapy handling should not be treated as an OSHA compliance certificate for the facility.

Approval checklist for hospital and pharmacy buyers

A practical approval file for USP 800 chemotherapy compounding gloves should include the following evidence. Product identity: exact manufacturer, brand, material, sterile or nonsterile format, size range, catalog identifier, and packaging configuration. Standard evidence: ASTM D6978 chemotherapy permeation report or controlled summary for the candidate glove. USP alignment: powder-free status, chemotherapy-tested claim, sterile outer chemotherapy glove option for sterile compounding, and documented change interval. Use controls: inspection before use, handwashing after removal, donning and doffing instructions, and disposal instructions consistent with hazardous-drug SOPs. The checklist should also include review ownership. Pharmacy should confirm task fit for compounding and administration. Infection prevention should confirm sterile-use expectations. EHS should confirm hazardous-drug handling and worker-protection alignment. Procurement should confirm that substitutions require technical review, not only price approval. Quality should retain the evidence file and supplier document revision level so a future catalog substitution does not silently change the approved glove. The key trade-off is between convenience and evidence depth. A broad distributor brochure can help identify candidate products, but it is not enough for final approval if the facility needs task-specific chemotherapy permeation proof. A complete test report may take longer to obtain, but it gives reviewers a clearer basis for deciding whether the glove fits the hazardous-drug task.

How to compare candidate gloves without overclaiming

When comparing candidate gloves, avoid ranking products by a single marketing phrase such as chemotherapy tested. Start with exclusion criteria: no ASTM D6978 evidence, no powder-free confirmation, no sterile option when sterile compounding requires it, or no way to match the evidence to the exact glove. A glove that fails those gates should not advance until the missing evidence is supplied and reviewed. For gloves that pass the basic gates, compare operational fit. Pharmacy compounders may need tactile control, reliable cuff coverage under gowning, dispenser compatibility, and packaging that supports controlled storage. EHS may care about replacement interval, training clarity, and whether the supplier explains limitations. Procurement may care about substitution control and evidence retention. None of those points proves compliance by itself, but together they reduce the chance that a low-evidence glove enters a high-risk hazardous-drug workflow. The final approval question should be phrased narrowly: is this exact glove, supported by this exact evidence package, acceptable for these named hazardous-drug tasks under the facility's SOPs? That question keeps the decision evidence-first and prevents a supplier's general USP 800 claim from being stretched beyond what the documents actually support.

Method for using the evidence in a buying decision

The source review behind this article compared public USP status material, USP FAQ guidance, and supplier-facing glove guidance. The sources were screened for dates, scope statements, NIOSH context, glove-change guidance, and ASTM D6978 references. Claims were included only where the supplied source text supported the specific buyer-facing point. This method supports preliminary procurement screening, not final clinical or legal approval. Buyers should use the data points below as an evidence index, then request current supplier documents and route them through pharmacy, EHS, infection prevention, and quality reviewers before approving a glove for compounding use. Where a source is a supplier brochure, treat it as a lead for document requests, not as independent proof that the submitted glove is suitable for every hazardous-drug task.

Confirm the specification in writing

Use this article as a starting point. Ask GloveMark for written, project-specific confirmation of materials, MOQ, pricing, sample policy, certification scope and lead time before placing an order.

Request project-specific confirmation →

Keep Reading

• High-Pressure Water Jetting Gloves: Evidence Checks for B2B Buyers
• Disposable Glove Grades Explained: Exam vs Industrial, Mil Thickness and AQL
• Nitrile vs Latex vs Vinyl Gloves: Which Disposable Glove Should You Buy?
• Glove Testing Labs Explained: SGS, Intertek, Bureau Veritas and What the Reports Cost
• Cleanroom Gloves: Sourcing for ISO Classes, Low Particles and Controlled Packaging